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STUDY QUESTION: What is the prevalence and functional consequence of ANOS1 (KAL1) mutations in a group of men with congenital
hypogonadotropic hypogonadism (CHH)?
SUMMARY ANSWER: Three of forty-two (7.1%) patients presented ANOS1 mutations, including a novel splice site mutation leading to
exon skipping and a novel contiguous gene deletion associated with ichthyosis.
WHAT IS KNOWN ALREADY: CHH is characterized by lack of pubertal development and infertility, due to deﬁcient production, secre-
tion or action of GnRH, and can be associated with anosmia/hyposmia (Kallmann syndrome, KS) or with a normal sense of smell (normosmic
CHH). Mutations in the anosmin-1 (ANOS1) gene are responsible for the X-linked recessive form of KS.
STUDY DESIGN, SIZE, DURATION: This cross-sectional study included 42 unrelated men with CHH (20 with KS and 22 with normos-
mic CHH).
PARTICIPANTS/MATERIALS, SETTING, METHODS: Patients were screened for mutations in the ANOS1 gene by DNA sequen-
cing. Identiﬁed mutations were further investigated by RT-PCR analysis and multiplex ligation-dependent probe ampliﬁcation (MLPA) analysis.
MAIN RESULTS AND THE ROLE OF CHANCE: Hemizygous mutations were identiﬁed in three (7.1%) KS cases: a novel splice
acceptor site mutation (c.542-1G>C), leading to skipping of exon 5 in the ANOS1 transcript in a patient with self-reported normosmia (but
hyposmic upon testing); a recurrent nonsense mutation (c.571C>T, p.Arg191*); and a novel 4.8 Mb deletion involving ANOS1 and eight other
genes (VCX3B, VCX2, PNPLA4, VCX, STS, HDHD1, VCX3A and NLGN4X) in KS associated with ichthyosis.
LIMITATIONS, REASONS FOR CAUTION: Objective olfactory testing was not performed in all cases of self-reported normosmia and
this may have underestimated the olfactory deﬁcits.
WIDER IMPLICATIONS OF THE FINDINGS: This study further expands the spectrum of known genetic defects associated with CHH
and suggests that patients with self-reported normal olfactory function should not be excluded from ANOS1 genetic testing.
STUDY FUNDING/COMPETING INTEREST(S): This study was funded by the Portuguese Foundation for Science and Technology.
The authors have no conﬂicts of interest.
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Introduction
Congenital hypogonadotropic hypogonadism (CHH) is characterized
by complete or partial failure of pubertal development due to deﬁcient
production, secretion or action of GnRH. Under normal conditions,
GnRH is produced by specialized hypothalamic neurons and stimulates
the release of gonadotropins (LH and FSH) from the pituitary, which
control gonadal maturation and adult reproductive physiology (Boehm
et al., 2015).
CHH includes Kallmann syndrome (KS), which is characterized by
gonadotropin deﬁciency with a defective sense of smell (i.e. anosmia
or hyposmia), and CHH without olfactory defects (normosmic CHH).
Other non-reproductive phenotypes, such as renal agenesis, midline
facial defects, dental agenesis, hearing loss, synkinesis and skeletal
anomalies, are commonly observed in patients with CHH (Costa-
Barbosa et al., 2013; Della Valle et al., 2013).
Up to 50% of patients with CHH reveal a genetic defect in genes
that regulate embryonic development or migration of GnRH neurons,
or the synthesis, secretion or action of GnRH (Boehm et al., 2015).
The identiﬁcation of genes mutated in patients with CHH has
improved the understanding of the neuroendocrine control of repro-
duction (Forni and Wray, 2015).
The anosmin-1 gene (ANOS1; MIM 300836), also known as the
Kallmann syndrome 1 (KAL1) gene, is one of the most commonly
involved genes in CHH and is responsible for the X-linked recessive
form of KS (Franco et al., 1991; Legouis et al., 1991). ANOS1 is
located on chromosome Xp22.31, comprises 14 exons and encodes
a 680-amino acid extracellular cell adhesion protein, anosmin-1, that
is essential for axonal guidance and migration of olfactory and GnRH
neurons from the nasal placode to their ﬁnal destination (Hu and
Bouloux, 2011).
The aim of this study was to identify and determine the prevalence
of ANOS1mutations in a group of men with CHH.
Materials andMethods
Subjects
The study comprised 42 unrelated Portuguese males with CHH, 20 with
KS and 22 with normosmic CHH, recruited by Portuguese clinical endo-
crine centres. Inclusion criteria were male patients with low serum FSH,
LH and testosterone levels and failure to enter spontaneous puberty by
the age of 18 years or with medically induced puberty below this age.
Olfactory function was assessed either by olfaction testing or by self-
reporting by the patients, depending on the clinical centre. Patients with a
history of an acquired cause of hypopituitarism or with abnormal radio-
logical imaging of the hypothalamic-pituitary region were excluded from
the study. In mutation-positive patients, additional family members were
also studied. The control population consisted of 85 (34 male, 51 female)
Portuguese unrelated volunteers who were recruited among blood
donors. Written informed consent was obtained from all subjects and the
study was approved by the local research ethics committee (Faculty of
Health Sciences, University of Beira Interior, Ref: CE-FCS-2012-012).
DNA sequence analysis
Genomic DNA was extracted from peripheral blood leucocytes using pre-
viously described methods (Miller et al., 1988). Patients were screened for
mutations in ANOS1 by PCR ampliﬁcation of the 14 coding exons and
exon–intron boundaries, and bidirectional sequencing using CEQ DTCS
sequencing kit (Beckman Coulter, Fullerton, CA, USA) and an automated
capillary DNA sequencer (GenomeLab TM GeXP, Genetic Analysis
System, Beckman Coulter). Primer sequences were previously described
(Hardelin et al., 1993), except for the forward primer for exon 1
(5’-TGGGAGGGAGGTCGGCGAGGAGGG-3’) and the reverse primer
for exon 10 (5’-GTGAATGGATAAAAGAATGAGTGA-3’), which were
designed using Primer 3 Plus (Untergasser et al., 2007). Background ampliﬁ-
cation of the KAL pseudogene (KALP) on chromosome Y, which occurred
frequently with exons 11–14 of ANOS1, was disregarded in the sequence
analysis of ANOS1. Genomic sequence variants identiﬁed in patients were
searched in population variant databases (Exome Aggregation Consortium
(ExAC) database) (ExAC, 2016) to assess their frequency in the general
population. Point mutations were conﬁrmed in patients and excluded in a
panel of 85 healthy volunteers (136 alleles) using a sequence-speciﬁc restric-
tion enzyme (EcoNI), in the case of the intron 4 mutation, or allele-speciﬁc
PCR, in the case of the exon 5 mutation. The latter was carried out by
multiplex PCR using a modiﬁed mutation-speciﬁc forward primer (5’-
AAGCCCAGAAAAGAGTGAT-3’) (modiﬁed nucleotides underlined)
together with the exon 5 pair of PCR primers. The functional consequences
of the observed splice site mutation were predicted using the Mutation
Taster (Schwarz et al., 2010) and Human Splicing Finder (Desmet et al.,
2009) bioinformatics tools. Mutation nomenclature followed standard
guidelines (den Dunnen and Antonarakis, 2001) and was based on the
cDNA reference sequence for ANOS1 (GenBank accession NM_000
216.2). Patients with identiﬁed ANOS1 mutations were screened for
digenic/oligogenic mutations by sequencing additional genes related to
the hypothalamic-pituitary-gonadal axis (FGFR1, GNRH1, GNRHR, FGF8,
PROK2, PROKR2, KISS1R, TAC3, TACR3 and CHD7) (all primer sequences
and PCR conditions are available upon request).
RT-PCR analysis
In patients with splice site mutations, RT-PCR was used to investigate
mRNA splicing abnormalities, using total RNA extracted from peripheral
blood leucocytes from the proband and an unrelated normal individual, as
previously described (Infante et al., 2016). RT-PCR was performed using
ANOS1-speciﬁc primers consisting of a forward primer 5’-AATGTTC
TAAGTGCCTGGAGCC-3’ (spanning the junction of exons 2 and 3) and
a reverse primer 5’-CAGAATTTTGAAACCCATCCGTAG-3’ (spanning
the junction of exons 7 and 8), and using 35 cycles with an annealing tem-
perature of 56°C and with 1.5 mM MgCl2. The RT-PCR products were
then sequenced as described above.
Multiplex ligation-dependent probe
ampliﬁcation analysis
In patients with absence of PCR ampliﬁcation of the ANOS1 exons, the
multiplex ligation-dependent probe ampliﬁcation (MLPA) technique was
used to conﬁrm the deletion of the gene. ANOS1 gene dosage analysis was
carried out using the commercial SALSA MLPA Probemix P018-F1 SHOX
(MRC Holland, Amsterdam, The Netherlands) that comprises probes for
several genes including ANOS1. Patient and control samples were prepared
according to the manufacturer’s instructions (MRC Holland). Amplicons
were run on an automated capillary DNA sequencer and analysed by frag-
ment analysis software (GenomeLab TM GeXP, Genetic Analysis System,
Beckman Coulter).
Identiﬁcation of deletion boundaries
In patients with a complete ANOS1 gene deletion, the extent of the dele-
tion was determined by PCR ampliﬁcation of known genetic markers
(NCBI Map Viewer, National Center for Biotechnology Information, US
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National Library of Medicine, Bethesda, MD, USA) upstream and down-
stream of the ANOS1 locus, and further reﬁned until the closest ampliﬁed
markers were identiﬁed.
Results
Sequence analysis of the entire coding region of ANOS1, including
exon–intron boundary regions, revealed three different hemizygous
mutations: a splice acceptor site mutation in intron 4 (c.542-1G>C), a
nonsense mutation in exon 5 (c.571C>T, p.Arg191*), and a complete
deletion of ANOS1 (Figs 1 and 2). Screening of additional CHH genes
in these three patients revealed no other mutations.
The c.542-1G>C and c.571C>T mutations were conﬁrmed in
patients and excluded in a panel of 85 normal controls (136 alleles),
by restriction enzyme (EcoNI) analysis and allele-speciﬁc PCR,
respectively (Fig. 1C). Furthermore, these variants were not found in
any of the population variant databases including the ExAC database
(ExAC, 2016).
Bioinformatics analysis predicted that the splice site mutation was
likely to have a damaging effect on splicing. Further assessment by RT-
PCR analysis revealed that the patient’s leucocyte ANOS1 transcript was
shorter than the wild-type transcript obtained from a control sample
(Fig. 3A). Sequence analysis of the cDNA showed that the mutated tran-
script was 185 nucleotides shorter than the wild-type (r.542_726del)
and that the missing sequence corresponded to exon 5 (Fig. 3B).
Thus, the splice acceptor site mutation in intron 4 was found to result
in the skipping of exon 5 in the ANOS1 transcript (Fig. 3C). If trans-
lated, the mutated transcript would be expected to result in a trun-
cated protein due to a frameshift and premature termination codon
(p.Gly181Aspfs*10). A possible effect of the mutation on nonsense-
mediated mRNA decay was not assessed.
A complete deletion of ANOS1 was suspected in one of the patients
due to the repeated failure of PCR ampliﬁcation of the 14 ANOS1
exons. MLPA analysis conﬁrmed that a deletion had occurred in the
ANOS1 gene (Fig. 2B) and also in the nearby NLGN4X gene (data not
shown). PCR ampliﬁcation of genetic markers in the proximity of the
ANOS1 locus was performed to determine the extent of the deletion
Figure 1 Identiﬁcation of ANOS1 point mutations in affected individuals. (A) Pedigrees of affected individuals. Squares denote males and circles
denote females, ﬁlled symbols represent patients with congenital hypogonadotropic hypogonadism (CHH), open symbols represent unaffected indivi-
duals, oblique lines through symbols represent deceased individuals, double slash indicates divorce, arrows indicate the index cases. The results of gen-
etic testing are represented under each individual, as hemizygous males with the mutation (+/0), and heterozygous females (+/−). (B) DNA
sequence analysis of normal individuals (above) and patients (below). The positions of the mutations are indicated by asterisks. Patients are hemizygous
for the mutated nucleotides whereas unaffected female carriers (not shown) are heterozygous. (C) Conﬁrmation of mutations by agarose gel electro-
phoresis of EcoNI restriction enzyme digested fragments and allele-speciﬁc PCR, respectively. Lanes correspond to family members represented in
panel (A) and normal controls (C). bp, base-pairs.
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and this revealed that the deletion spanned a region of ~4.8 mega-
bases (Mb). This deleted region affected several genes (ordered to-
wards the telomere): ANOS1, VCX3B, VCX2, PNPLA4, VCX, STS,
HDHD1, VCX3A and NLGN4X (Fig. 2C).
Additional family members were screened for the identiﬁed muta-
tions and this showed segregation of the mutations with the disorder,
in an X-linked recessive inheritance pattern (Figs 1A and 2A). The
clinical characteristics of patients with identiﬁed ANOS1 mutations are
summarized in Table I.
The nonsense mutation and the complete deletion of ANOS1
occurred in patients with anosmia (i.e. KS), whereas the splice site
mutation occurred in two brothers with apparently normal olfaction.
As ANOS1 mutations occur only rarely in normosmic CHH, this
prompted us to re-evaluate these patients for whom olfaction ability
Figure 2 Identiﬁcation of an ANOS1 whole gene deletion. (A) Pedigree of the affected individuals. Squares denote males and circles denote females,
ﬁlled symbols represent patients with CHH, open symbols represent unaffected individuals, arrow indicates the index case. The observed genotypes
are represented under each individual, as hemizygous males with (+/0) and without (−/0) the mutation, and heterozygous (+/−) and normal homozy-
gous (−/−) females. (B) Multiplex ligation-dependent probe ampliﬁcation (MLPA) analysis of family members and a normal female control (C).
Arrows indicate the location of the 237-bp probe signal corresponding to ANOS1, which is absent (asterisk) in the patients (II-1 and II-2) and present in
the normal hemizygous father (I-1), normal heterozygous mother (I-2), and normal homozygous female control. A 240-bp DNA size marker is repre-
sented in red. (C) Schematic representation of the Xp22.32-p22.31 region (oriented from telomere (left) to centromere (right)) showing the genes
that are deleted in the patients and the genetic markers used to assess the limits of the deletion. The presence (+) and absence (−) of the markers indi-
cate that the deletion extends ~4.8 megabases (Mb). A 0.5-Mb scale bar is shown.
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had been self-reported as normal. Olfaction testing in these individuals
revealed hyposmia in both. MRI of the olfactory bulbs and tracts in
these patients was not performed because one of the brothers had
ﬁxed orthodontic braces and the other declined the exam.
Discussion
We identiﬁed three different ANOS1 mutations in 42 unrelated male
patients with CHH. These consisted of a novel splice acceptor site
mutation (c.542-1G>C), a previously reported nonsense mutation
(c.571C>T; p.Arg191*) (Oliveira et al., 2001), and a novel 4.8-Mb con-
tiguous gene deletion in the Xp22.31-p22.32 region that included the
ANOS1 locus. These mutations are predicted to be highly deleterious as
the splice site mutation was found to result in exon skipping and the
production of an abnormal mRNA, nonsense mutations result in pre-
mature stop codons that lead to the production of truncated proteins
or to nonsense-mediated mRNA decay (Baker and Parker, 2004), and
whole gene deletions result in complete absence of gene expression.
Further evidence for the pathogenicity of the mutations came from the
demonstration of their presence in additional family members with the
same phenotype as the patients and their absence in normal individuals.
The prevalence of ANOS1 mutations in the literature varies between
10 and 20% in male patients with KS (Semple and Topaloglu, 2010; Hu
and Bouloux, 2011), but is exceptionally rare in patients with normal
olfaction. Sato et al. (2004) reported a case of normosmic CHH with
an ANOS1 mutation, however, even this case had hypoplastic, rather
than normal, olfactory bulbs on MRI. Another patient reported in the
same study was allegedly normosmic until his early twenties and had
hyposmia from his late twenties. More recently, Li et al. (2016)
reported two children with ANOS1 mutations, and with normal olfac-
tion and normal MRIs.
Given that ANOS1 mutations occur almost exclusively in patients
with olfactory defects, our ﬁnding of two brothers with an ANOS1
mutation and self-reported normal olfaction led us to re-evaluate
these patients through olfaction testing and this did indeed reveal
hyposmia in both. Thus, this conﬁrms previous observations that self-
reported olfactory assessment may underestimate the true olfactory
deﬁcit in some cases of CHH (Lewkowitz-Shpuntoff et al., 2012; Jagtap
et al., 2013) and suggests that male patients with self-reported normal
olfactory function should not be excluded from ANOS1 genetic testing.
Our study identiﬁed a submicroscopic chromosomal deletion in a
patient with KS. Although whole or partial ANOS1 gene deletions are
common in KS (Pedersen-White et al., 2008; Montenegro et al.,
2013), the deletion identiﬁed in this patient extended along a 4.8-Mb
region that contains several genes (i.e. ANOS1, VCX3B, VCX2, PNPLA4,
VCX, STS, HDHD1, VCX3A and NLGN4X). Thus, this represents a con-
tiguous gene deletion and explains why the patient has additional
phenotypic features, such as ichthyosis and cognitive delay, which are
not directly related to KS. In particular, mutations in STS (Steroid
Sulphatase; MIM 300747) are responsible for X-linked ichthyosis, a
genetic disorder of keratinization, characterized by generalized des-
quamation of the skin (Hernandez-Martin et al., 1999); and mutations
in NLGN4X (Neuroligin 4; MIM 300427) and VCX3A (Variably
Charged, X chromosome, 3 A; MIM 300533) have been implicated in
autism and mental retardation (Fukami et al., 2000; Jamain et al.,
2003). Two similar deletions of 4.5 Mb (Macarov et al., 2007) and
3.7 Mb (Mochel et al., 2008), affecting the same set of genes, have
been reported previously, and were associated with KS, ichthyosis and
normal to mildly affected intellectual ability.
Our study also highlights the clinical heterogeneity of phenotypes that
often challenge clinicians and hinder targeted genetic diagnostic testing.
The variability of clinical manifestations, such as the severity of olfactory
deﬁcits, renal abnormalities or neurological signs (such as synkinesis or
mirror movements) found among families and even within the same
family, suggests a possible role of modiﬁer genes, and/or epigenetic fac-
tors, in determining the variable expressivity of the disease. Although we
searched for oligogenicity by sequencing other commonly affected CHH
genes, other rarer loci were not analysed and it remains to be deter-
mined if a more comprehensive genetic analysis (e.g. through whole
exome sequencing) would help elucidate the phenotypic variability.
Figure 3 Functional consequences of the splice acceptor site muta-
tion identiﬁed in Family 1. (A) Agarose gel electrophoresis of RT-PCR
fragments obtained from ANOS1 transcripts in leucocytes from patient
III-1 and a normal control (C). An 831-bp band was observed in con-
trols, but only a 646-bp band was observed in the patient. A 100-bp
ladder molecular-weight marker (m) is shown. (B) Sequence analysis
of the RT-PCR product obtained from the patient demonstrated the
loss of 185 nucleotides corresponding to exon 5 on the ANOS1 tran-
script and that exon 4 was spliced on to exon 6. (C) Schematic
representation of normal and abnormal splicing of the ANOS1 exons
(numbered boxes). The use of the normal splice acceptor site before
exon 5 leads to the synthesis of a normal sized mRNA transcript.
However, in the presence of the mutation (c.542-1G>C), the normal
splice acceptor site is no longer recognized causing skipping of exon 5
and a shorter mutated mRNA transcript.
708 Gonçalves et al.
In conclusion, this study identiﬁed novel ANOS1 mutations in
patients with CHH, thus expanding the known spectrum of ANOS1
mutations, and suggests that patients with self-reported normal
olfactory function should not be excluded from ANOS1 genetic
testing.
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Table I Clinical characteristics of patients with ANOS1mutations.
Family Member
(a)
Sex Age of
diagnosis
(years)
Clinical
presentation
Olfaction
(b)
Associated features Basal hormone
levels (normal
reference
range)
Brain MRI ANOS1
mutation
1 III-1 M 15.0 Delayed puberty.
Tanner stage 2.
Testicular volume 2 ml
Normal (c) Right renal agenesis FSH 0.4 mIU/ml
(0.8–8.2); LH 0.1
mIU/ml (0.7–7.2);
total testosterone
0.20 ng/ml
(2.20–8.00)
n/a c.542
−1G>C
III-2 M 15.8 Delayed puberty.
Tanner stage 2.
Testicular volume 2 ml
Normal (c) Right renal agenesis.
Attention deﬁcit
hyperactivity disorder
FSH 0.1 mIU/ml
(0.8–8.2); LH 0.3
mIU/ml (0.7–7.2);
total testosterone
0.10 ng/ml
(2.20–8.00)
n/a c.542
−1G>C
2 II-5 M 43 Delayed puberty.
Tanner stage 1.
Bilateral cryptorchidism
(2/3 ml testes in
inguinal canals).
Micropenis. Synkinesis
(very mild)
Anosmia Normal kidneys. Low
bone mineral density
(lumbar spine T/Z-score
−2.1/−2.9; femoral neck
T/Z-score 0.8/0.6)
FSH 0.7 mIU/ml
(1.5–12.4); LH 0.1
mIU/ml (1.7–8.6);
total testosterone
0.35 ng/ml
(2.80–8.00)
Bilateral
agenesis of
the olfactory
bulbs and
tracts
c.571C>T
(p.Arg191*)
II-9 M 34 Delayed puberty.
Tanner stage 1.
Bilateral cryptorchidism
(3 ml testes in inguinal
canals). Micropenis
Anosmia Normal kidneys. Low
bone mineral density
(lumbar spine T/Z-score
−2.5/−2.8; femoral neck
T/Z-score −1.0/−1.1)
FSH 0.8 mIU/ml
(1.5–12.4); LH 0.3
mIU/ml (1.7–8.6);
total testosterone
0.29 ng/ml
(2.80–8.00)
Bilateral
agenesis of
the olfactory
bulbs and
tracts
c.571C>T
(p.Arg191*)
III-1 M 21 Delayed puberty.
Tanner stage 1.
Bilateral cryptorchidism
(1 ml testes in inguinal
canals). Micropenis
Anosmia Low bone mineral density
(lumbar spine T/Z-score
−2.4/−2.3; femoral neck
T/Z-score −1.3/−1.4).
Renal imaging n/a
FSH 0.4 mIU/ml
(1.5–12.4);
LH < 0.4 mIU/ml
(1.7–8.6); total
testosterone 0.15
(2.80–8.00)
n/a c.571C>T
(p.Arg191*)
3 II-1 M 17.1 Delayed puberty.
Tanner stage 1.
Testicular volume 2 ml
Anosmia Right renal agenesis.
Ichthyosis. Cognitive
delay. Short stature (SDS
−2.81). Delayed bone age
(13.0 yr). Morbid obesity
(BMI 43.6 kg/m2)
FSH 0.4 mIU/ml
(0.8–8.2); LH 0.1
mIU/ml (0.7–7.2);
total testosterone
0.25 ng/ml
(2.60–10.00)
Bilateral
hypoplastic
olfactory
bulbs tracts
and sulci
contiguous
gene
deletion
II-2 M 10.8 Bilateral cryptorchidism n/a Normal kidneys.
Ichthyosis. Cognitive
delay. Normal stature
(SDS 0.53). Obesity (BMI
28.8 Kg/m2, SDS 3.04)
n/a Bilateral
hypoplastic
olfactory
bulbs and
tracts, and
hypoplasia of
right sulcus
contiguous
gene
deletion
(a) As indicated in Figs 1 and 2; (b) self-reported; (c) Reclassiﬁed as hyposmia after undergoing an in-house psychophysical olfactory test, by asking the patient to identify the odour of
ground coffee beans, cocoa, pepper, cinnamon and vinegar in an opaque container placed beneath each nostril (patients were able to detect the odours, but were unable to discrimin-
ate any of the substances, except vinegar); M, male; n/a, not available; SDS, standard deviation score. Hormone levels were measured by chemiluminescence immunoassays. Bone
mineral density was measured by dual-energy X-ray absorptiometry. Kidneys were assessed by renal ultrasonography. All patients (except II-2 from Family 3, who was pre-pubertal)
were treated with regular intramuscular injections of testosterone enanthate resulting in improvement of secondary sexual characteristics, muscle strength and subjective well-being.
None of the patients has so far undergone fertility induction.
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